Atypical femoral fracture in a patient treated with denosumab

Journal of Bone and Mineral Metabolism

Volumn 33, Issue 3, 2015, Pages 355-358

  Khow, Kareeann Sok Fun ^a   Yong, Tuck Yean ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Flinders Private Hospital   (Australia)

Author keywords

Atypical femoral fractures; Denosumab; Osteoporosis

Indexed keywords

BONE DENSITY CONSERVATION AGENT; DENOSUMAB;

AGED; CASE REPORT; FEMALE; FEMORAL FRACTURES; HUMAN; OSTEOPOROSIS; RADIOGRAPHY;

AGED; BONE DENSITY CONSERVATION AGENTS; DENOSUMAB; FEMALE; FEMORAL FRACTURES; HUMANS; OSTEOPOROSIS;

EID: 84936759815     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-014-0606-6     Document Type: Article

References (17)

1. Giannini S, Chiarello E, Tedesco G, Cadossi M, Luciani D, Mazzotti A, Donati DM (2013) Atypical femoral fractures. Clin Cases Miner Bone Metab 10:30–33
2. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23
3. Diab DL, Watts NB (2014) Denosumab in osteoporosis. Expert Opin Drug Saf 13:247–253
4. Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E et al (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4483–4492
5. Paparodis R, Buehring B, Pelley EM, Binkley N (2013) A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 19:e64–e68
6. Thompson RN, Armstrong CL, Heyburn G (2013) Bilateral atypical femoral fractures in a patient prescribed denosumab--A case report. Bone 61C:44–47
7. Villiers J, Clark DW, Jeswani T, Webster S, Hepburn AL (2013) An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab. Case Rep Rheumatol 2013:249872
8. Drampalos E, Skarpas G, Barbounakis N, Michos I (2014) Atypical femoral fractures bilaterally in a patient receiving denosumab. Acta Orthop 85:3–5
9. Schilcher J, Aspenberg P (2014) Atypical fracture of the femur in a patient using denosumab--a case report. Acta Orthop 85:6–7
10. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765
11. Denosumab 60 mg: rare cases of atypical femoral fracture with long-term use. MHRA Drug Safety Update 2013 Volume 6, Issue 7. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON2394 (accessed 1/4/2014)
12. MHRA drug analysis print. http://www.mhra.gov.uk/home/groups/public/documents/sentineldocuments/dap_1374834463819.pdf. [accessed 1/4/2014]
13. FDA Adverse Event Reporting System (FAERS): latest quarterly data files. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm. [accessed 1/4/2014]
14. Li J, Miller MA, Hutchins GD, Burr DB (2005) Imaging bone microdamage in vivo with positron emission tomography. Bone 37:819–824
15. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–1061
16. Ettinger B, Burr DB, Ritchie RO (2013) Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone 55:495–500
17. Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 52:360–365